Quick Answer
ANI PHARMACEUTICALS INC reported R&D Expense of $51.66 million for fiscal year 2025.
ANI PHARMACEUTICALS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $51.66M | +15.9% |
| 2024 | $44.58M | +30.0% |
| 2023 | $34.29M | +53.6% |
| 2022 | $22.32M | +96.3% |
| 2021 | $11.37M | -28.9% |
| 2020 | $16.00M | -19.2% |
| 2019 | $19.81M | +28.7% |
| 2018 | $15.39M | +69.7% |
| 2017 | $9.07M | +212.1% |
| 2016 | $2.91M | +1.1% |
| 2015 | $2.87M | +7.3% |
| 2014 | $2.68M | +56.4% |
| 2013 | $1.71M | +47.8% |
| 2012 | $1.16M | -97.4% |
| 2011 | $44.18M | +11.3% |
| 2010 | $39.71M | +190.2% |
| 2009 | $13.68M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $12.30M | +21.5% | -25.6% |
| June 30, 2025 | $16.54M | +126.6% | +56.5% |
| March 31, 2025 | $10.56M | +0.5% | +4.3% |
| September 30, 2024 | $10.13M | -8.9% | +38.8% |
| June 30, 2024 | $7.30M | -1.1% | -30.6% |
| March 31, 2024 | $10.51M | +77.4% | -5.5% |
| September 30, 2023 | $11.12M | +45.2% | +50.8% |
| June 30, 2023 | $7.37M | +77.0% | +24.5% |
- ANI PHARMACEUTICALS INC showed an increase of +15.9% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, ANI PHARMACEUTICALS INC’s r&d expense has grown by 277.6% (from $13.68 million to $51.66 million).
- The most recent figure is from ANI PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: